{"id":"tegafur","rwe":[],"tags":[{"label":"tegafur","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01BC03","category":"atc"},{"label":"Active","category":"status"},{"label":"HER2negative breast cancer","category":"indication"},{"label":"Hormone receptor pozitive breast cancer","category":"indication"},{"label":"Malignant tumor of stomach","category":"indication"},{"label":"Nordic Group BV","category":"company"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antimetabolites, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":82.921,"date":"","count":25,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=83)"},{"llr":59.262,"date":"","count":18,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=59)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Nordic Group BV","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TEGAFUR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:21:22.518084+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:21:28.301419+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:21:22.589605+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TEGAFUR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:21:28.548272+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL235993/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:29.235141+00:00"}},"allNames":"florafur","offLabel":[],"synonyms":["tegafur","ftorafur","FT-207","florafur","futraful"],"timeline":[{"date":"1999-03-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Taiho Pharmaceutical Co, Ltd)"},{"date":"2011-03-14","type":"positive","source":"DrugCentral","milestone":"EMA approval (Nordic Group BV)"}],"approvals":[{"date":"1999-03-01","orphan":false,"company":"Taiho Pharmaceutical Co, Ltd","regulator":"PMDA"},{"date":"2011-03-14","orphan":false,"company":"Nordic Group BV","regulator":"EMA"}],"brandName":"Florafur","ecosystem":[{"indication":"HER2negative breast cancer","otherDrugs":[],"globalPrevalence":null},{"indication":"Hormone receptor pozitive breast cancer","otherDrugs":[],"globalPrevalence":null},{"indication":"Malignant tumor of stomach","otherDrugs":[{"name":"capecitabine","slug":"capecitabine","company":"Hoffmann La Roche"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"tegafur","explanation":"","oneSentence":"","technicalDetail":"Florafur is a prodrug that is metabolized to 5-fluorouracil (5-FU), which then inhibits thymidylate synthase through the formation of a covalent complex, thereby disrupting DNA synthesis and leading to cell death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4398","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TEGAFUR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TEGAFUR","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T15:49:16.407991","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:30.846550+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cytarabine","drugSlug":"cytarabine","fdaApproval":"1969-06-17","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fluorouracil","drugSlug":"fluorouracil","fdaApproval":"1962-04-25","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gemcitabine","drugSlug":"gemcitabine","fdaApproval":"1996-05-15","patentExpiry":"Jun 28, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"capecitabine","drugSlug":"capecitabine","fdaApproval":"1998-04-30","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azacitidine","drugSlug":"azacitidine","fdaApproval":"2004-05-19","patentExpiry":"May 14, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"decitabine","drugSlug":"decitabine","fdaApproval":"2006-05-02","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"floxuridine","drugSlug":"floxuridine","fdaApproval":"1970-12-18","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trifluridine","drugSlug":"trifluridine","fdaApproval":"1980-04-10","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"tegafur","indications":{"approved":[{"name":"HER2negative breast cancer","source":"DrugCentral","snomedId":767444009,"regulator":"FDA"},{"name":"Hormone receptor pozitive breast cancer","source":"DrugCentral","snomedId":417181009,"regulator":"FDA"},{"name":"Malignant tumor of stomach","source":"DrugCentral","snomedId":363349007,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cytarabine","brandName":"cytarabine","genericName":"cytarabine","approvalYear":"1969","relationship":"same-class"},{"drugId":"fluorouracil","brandName":"fluorouracil","genericName":"fluorouracil","approvalYear":"1962","relationship":"same-class"},{"drugId":"gemcitabine","brandName":"gemcitabine","genericName":"gemcitabine","approvalYear":"1996","relationship":"same-class"},{"drugId":"capecitabine","brandName":"capecitabine","genericName":"capecitabine","approvalYear":"1998","relationship":"same-class"},{"drugId":"azacitidine","brandName":"azacitidine","genericName":"azacitidine","approvalYear":"2004","relationship":"same-class"},{"drugId":"decitabine","brandName":"decitabine","genericName":"decitabine","approvalYear":"2006","relationship":"same-class"},{"drugId":"floxuridine","brandName":"floxuridine","genericName":"floxuridine","approvalYear":"1970","relationship":"same-class"},{"drugId":"trifluridine","brandName":"trifluridine","genericName":"trifluridine","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07502027","phase":"PHASE4","title":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2026-06-01","conditions":["Gastric Cancer (Diagnosis)","Gastric Cancer (GC)","Gastroesophageal Junction Adenocarcinoma"],"enrollment":55,"completionDate":"2029-06-30"},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":["Locally Advanced Rectal Carcinoma"],"enrollment":394,"completionDate":"2034-03-02"},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":["Gastric Cancer"],"enrollment":226,"completionDate":"2027-07-31"},{"nctId":"NCT00905047","phase":"PHASE3","title":"Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-11-14","conditions":["Colorectal Cancer"],"enrollment":89,"completionDate":"2011-09"},{"nctId":"NCT07453875","phase":"PHASE1","title":"LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-02-09","conditions":["Peritoneal Metastasis of Gastric and Colorectal Cancer","LDRT"],"enrollment":9,"completionDate":"2027-12-30"},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":["Biliary Tract Cancer"],"enrollment":757,"completionDate":"2030-05-03"},{"nctId":"NCT06461910","phase":"PHASE2","title":"Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zekuan Xu","startDate":"2024-06-14","conditions":["Gastric Cancer","Esophagogastric Junction Adenocarcinoma"],"enrollment":30,"completionDate":"2027-12"},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":["Advanced Biliary Tract Carcinoma"],"enrollment":30,"completionDate":"2026-12-03"},{"nctId":"NCT07023315","phase":"PHASE3","title":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-08-14","conditions":["Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":760,"completionDate":"2031-07"},{"nctId":"NCT07386704","phase":"PHASE2","title":"Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University First Hospital","startDate":"2025-12-09","conditions":["Pancreatic Cancer Non-resectable"],"enrollment":30,"completionDate":"2027-12-09"},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":["Non-small Cell Lung Cancer","Gastric Cancer","Pancreatic Ductal Adenocarcinoma"],"enrollment":102,"completionDate":"2026-06-30"},{"nctId":"NCT07372300","phase":"PHASE3","title":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shih-Kai Hung","startDate":"2025-09-23","conditions":["Locally Advanced Rectal Carcinoma"],"enrollment":126,"completionDate":"2027-12-31"},{"nctId":"NCT06739252","phase":"PHASE2","title":"Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA","status":"TERMINATED","sponsor":"Peking University","startDate":"2024-12-31","conditions":["Intrahepatic Cholangiocarcinoma (Icc)","Perihilar Cholangiocarcinoma"],"enrollment":1,"completionDate":"2025-12-22"},{"nctId":"NCT06761846","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-17","conditions":["Gastric Adenocarcinoma","Esophagogastric Junction Adenocarcinoma"],"enrollment":70,"completionDate":"2028-12-31"},{"nctId":"NCT06808971","phase":"PHASE2","title":"Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-28","conditions":["Gastric Adenocarcinoma","Gastro-esophageal Junction Adenocarcinoma"],"enrollment":61,"completionDate":"2027-12-31"},{"nctId":"NCT07182565","phase":"PHASE1,PHASE2","title":"Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-18","conditions":["Gastroesophageal Junction Adenocarcinoma","Hypofractionated Radiotherapy"],"enrollment":84,"completionDate":"2029-08-31"},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":["Gastric Cancer Stage III"],"enrollment":74,"completionDate":"2030-12-31"},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":["Gastric Cancer Peritoneal Metastases"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":["Gastric Neoplasms","Gastroesophageal Junction Adenocarcinoma"],"enrollment":738,"completionDate":"2025-11-12"},{"nctId":"NCT03013010","phase":"PHASE3","title":"PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Shanghai Cancer Hospital, China","startDate":"2016-12","conditions":["Stomach Neoplasm","GastroEsophageal Cancer","Adenocarcinoma","Locally Advanced Cancer","Chemoradiation"],"enrollment":204,"completionDate":"2024-12-05"},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":["Metastatic Pancreatic Cancer"],"enrollment":320,"completionDate":"2028-06"},{"nctId":"NCT07178340","phase":"PHASE2","title":"Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-18","conditions":["Hepatoid Adenocarcinoma of Stomach"],"enrollment":30,"completionDate":"2028-09-20"},{"nctId":"NCT07194005","phase":"PHASE2","title":"Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-04","conditions":["Gastric Cancer"],"enrollment":30,"completionDate":"2028-09-30"},{"nctId":"NCT06992362","phase":"PHASE2","title":"Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-20","conditions":["Hepatoid Adenocarcinoma of Stomach"],"enrollment":30,"completionDate":"2029-12-31"},{"nctId":"NCT05934331","phase":"PHASE2","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","status":"RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2023-07-27","conditions":["Malignant Neoplasms of Digestive Organs"],"enrollment":276,"completionDate":"2028-07-01"},{"nctId":"NCT07165847","phase":"PHASE2","title":"Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-07-23","conditions":["Immunotherapy","Gastric Cancer (GC)","Radiotherapy","Neoadjuvant Therapy","Neoadjuvant Chemoimmunotherapy"],"enrollment":40,"completionDate":"2030-12-31"},{"nctId":"NCT07161453","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-09-30","conditions":["Gastric / Gastroesophageal Junction Adenocarcinoma"],"enrollment":500,"completionDate":"2027-12-31"},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":["Gastric Adenocarcinoma","Stomach Neoplasms"],"enrollment":54,"completionDate":"2030-10-01"},{"nctId":"NCT05149807","phase":"PHASE2,PHASE3","title":"Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-01-26","conditions":["Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer"],"enrollment":81,"completionDate":"2024-04-03"},{"nctId":"NCT02363400","phase":"PHASE3","title":"A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12-14","conditions":["Nasopharyngeal Carcinoma"],"enrollment":10,"completionDate":"2021-12-31"},{"nctId":"NCT07092449","phase":"NA","title":"Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-08-01","conditions":["Gastroesophageal Junction","Gastric / Gastroesophageal Junction Adenocarcinoma","Neoadjuvant Chemoimmunotherapy","Adjuvant Therapy"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT03636893","phase":"PHASE2","title":"Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-08-24","conditions":["Gastric Cancer","Chemotherapy Effect"],"enrollment":74,"completionDate":"2025-05-08"},{"nctId":"NCT06939439","phase":"PHASE3","title":"Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":["Gastric Cancer Stage III"],"enrollment":416,"completionDate":"2029-12-31"},{"nctId":"NCT07034742","phase":"EARLY_PHASE1","title":"Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-01","conditions":["Gastric Adenocarcinoma"],"enrollment":136,"completionDate":"2028-01-01"},{"nctId":"NCT05161572","phase":"PHASE2","title":"Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Fudan University","startDate":"2021-09-28","conditions":["Stomach Neoplasms","Esophagogastric Junction Disorder","Neoadjuvant Therapy","Chemoradiotherapy","Immunotherapy","Gastrectomy","Adenocarcinoma","Adjuvant Therapy"],"enrollment":6,"completionDate":"2022-09-30"},{"nctId":"NCT05170503","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-29","conditions":["Esophagogastric Junction Adenocarcinoma"],"enrollment":37,"completionDate":"2029-01-01"},{"nctId":"NCT01720563","phase":"PHASE2","title":"A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy","status":"TERMINATED","sponsor":"PhytoHealth Corporation","startDate":"2012-12","conditions":["Cancer-related Fatigue"],"enrollment":17,"completionDate":"2014-04"},{"nctId":"NCT06988956","phase":"PHASE2","title":"Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-03-31","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":95,"completionDate":"2027-04-01"},{"nctId":"NCT03406299","phase":"PHASE2","title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-19","conditions":["Biliary Tract Neoplasms"],"enrollment":92,"completionDate":"2024-12-31"},{"nctId":"NCT04415853","phase":"PHASE3","title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-01-21","conditions":["Esophageal Cancer"],"enrollment":416,"completionDate":"2026-12-30"},{"nctId":"NCT06422858","phase":"PHASE2","title":"Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-05-20","conditions":["Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma"],"enrollment":37,"completionDate":"2026-04"},{"nctId":"NCT06779318","phase":"PHASE4","title":"Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-07","conditions":["Pancreatic Cancer","Postoperative Adjuvant Therapy","Maintenance Therapy"],"enrollment":464,"completionDate":"2028-07"},{"nctId":"NCT05223088","phase":"PHASE2","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-10-31","conditions":["Immunotherapy","Gastrict Cancer"],"enrollment":40,"completionDate":"2024-04-30"},{"nctId":"NCT04863430","phase":"PHASE2","title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2021-05-11","conditions":["Gastric Cancer"],"enrollment":0,"completionDate":"2023-07-06"},{"nctId":"NCT03662659","phase":"PHASE2","title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-16","conditions":["Gastric Cancer","Cancer of the Stomach","Esophagogastric Junction"],"enrollment":274,"completionDate":"2024-01-18"},{"nctId":"NCT06427005","phase":"PHASE2","title":"Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC","status":"RECRUITING","sponsor":"Meng Qiu","startDate":"2023-02-20","conditions":["Fruquintinib","S-1","Raltitrexed"],"enrollment":66,"completionDate":"2026-04-30"},{"nctId":"NCT04260269","phase":"","title":"Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study","status":"ENROLLING_BY_INVITATION","sponsor":"Helsinki University Central Hospital","startDate":"2018-06-01","conditions":["Solid Tumor"],"enrollment":200,"completionDate":"2027-12"},{"nctId":"NCT03252808","phase":"PHASE1","title":"Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takara Bio Inc.","startDate":"2017-09-25","conditions":["Pancreatic Cancer Stage III","Pancreatic Cancer Stage IV"],"enrollment":36,"completionDate":"2035-03-31"},{"nctId":"NCT06662877","phase":"PHASE2,PHASE3","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-25","conditions":["Biliary Tract Cancer","Second Line Treatment","Chemotherapy","Tyrosine Kinase Inhibitor"],"enrollment":206,"completionDate":"2029-09-01"},{"nctId":"NCT03175679","phase":"PHASE1","title":"Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC","status":"COMPLETED","sponsor":"Beijing YouAn Hospital","startDate":"2017-04-01","conditions":["Hepatocellular Carcinoma"],"enrollment":10,"completionDate":"2019-03-30"},{"nctId":"NCT06603974","phase":"NA","title":"The Efficacy and Safety of Benmelstobart for GC/EGC","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-10-16","conditions":["Gastric Cancer"],"enrollment":48,"completionDate":"2026-12-26"},{"nctId":"NCT04515615","phase":"PHASE2","title":"Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yu jiren","startDate":"2020-09-09","conditions":["Gastric Cancer Stage III"],"enrollment":52,"completionDate":"2026-03-29"},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":["Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction"],"enrollment":361,"completionDate":"2014-08-15"},{"nctId":"NCT05144854","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-11-05","conditions":["Gastric Cancer"],"enrollment":626,"completionDate":"2027-05"},{"nctId":"NCT02454062","phase":"PHASE1","title":"A Trial of TAS-114 in Combination With S-1","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2013-03","conditions":["Advanced Solid Tumors"],"enrollment":120,"completionDate":"2017-09-30"},{"nctId":"NCT06525714","phase":"EARLY_PHASE1","title":"Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2024-08","conditions":["Gastric Cancer","Survival Rate"],"enrollment":302,"completionDate":"2030-07"},{"nctId":"NCT06354140","phase":"PHASE2","title":"PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-05-07","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":45,"completionDate":"2028-05-30"},{"nctId":"NCT06487702","phase":"PHASE2","title":"A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-07-10","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":70,"completionDate":"2027-06-10"},{"nctId":"NCT06196697","phase":"PHASE2","title":"AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-04-10","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"enrollment":50,"completionDate":"2027-03"},{"nctId":"NCT05498766","phase":"PHASE4","title":"Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-07-01","conditions":["Gastric Cancer"],"enrollment":702,"completionDate":"2029-11-01"},{"nctId":"NCT06439550","phase":"PHASE2","title":"Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-07-15","conditions":["HER2-positive Gastric Cancer"],"enrollment":42,"completionDate":"2026-12-31"},{"nctId":"NCT04799548","phase":"PHASE2","title":"A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-12-30","conditions":["Advanced Gastric Cancer"],"enrollment":71,"completionDate":"2026-01"},{"nctId":"NCT06368063","phase":"PHASE4","title":"The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Xi'an Jiaotong University","startDate":"2024-05-06","conditions":["Pancreatic Cancer Resectable"],"enrollment":642,"completionDate":"2028-03"},{"nctId":"NCT06396585","phase":"PHASE2","title":"The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-08-01","conditions":["Immunotherapy Gastroesophageal Junction"],"enrollment":28,"completionDate":"2026-08-31"},{"nctId":"NCT02746796","phase":"PHASE2,PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":["Gastric Cancer"],"enrollment":680,"completionDate":"2022-11-17"},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":["Gastric Cancer"],"enrollment":800,"completionDate":"2023-03-31"},{"nctId":"NCT06255379","phase":"PHASE2","title":"Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-05-06","conditions":["Metastasis Colorectal Cancer","Colon Cancer","Rectal Cancer"],"enrollment":52,"completionDate":"2027-03-21"},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":["Efficacy and Safety"],"enrollment":120,"completionDate":"2027-12-30"},{"nctId":"NCT06361316","phase":"NA","title":"Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Kuirong Jiang","startDate":"2024-04-08","conditions":["Pancreatic Cancer","Adjuvant Therapy"],"enrollment":53,"completionDate":"2028-07-31"},{"nctId":"NCT06339619","phase":"PHASE2","title":"Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-11","conditions":["Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma"],"enrollment":32,"completionDate":"2026-09-01"},{"nctId":"NCT06187597","phase":"PHASE2","title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":["Locally Advanced Esophageal Squamous Cell Carcinoma"],"enrollment":140,"completionDate":"2028-12-31"},{"nctId":"NCT06194734","phase":"PHASE3","title":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2024-02-05","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":490,"completionDate":"2027-12-30"},{"nctId":"NCT06283121","phase":"PHASE2","title":"A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2024-04-02","conditions":["Gastric Cancer, Metastatic"],"enrollment":30,"completionDate":"2027-11-30"},{"nctId":"NCT05122091","phase":"PHASE2","title":"Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-11-05","conditions":["Gastric Cancer","GastroEsophageal Cancer","Fruquintinib","SOX"],"enrollment":53,"completionDate":"2024-11-30"},{"nctId":"NCT04694183","phase":"PHASE2","title":"The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Quan Wang","startDate":"2020-08-17","conditions":["Stomach Neoplasms"],"enrollment":37,"completionDate":"2023-05-06"},{"nctId":"NCT05955157","phase":"PHASE2,PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":["Pancreatic Ductal Adenocarcinoma","Advanced Solid Tumor"],"enrollment":52,"completionDate":"2025-06"},{"nctId":"NCT01515748","phase":"PHASE3","title":"Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12-30","conditions":["Gastric Cancer"],"enrollment":530,"completionDate":"2021-12-13"},{"nctId":"NCT05960955","phase":"PHASE2","title":"Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-11-13","conditions":["Resectable Gastric or Gastroesophageal Junction Adenocarcinoma"],"enrollment":90,"completionDate":"2027-11-30"},{"nctId":"NCT06123455","phase":"PHASE2","title":"Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2023-08-01","conditions":["Gastric Cancer"],"enrollment":60,"completionDate":"2025-07-31"},{"nctId":"NCT03267121","phase":"PHASE2","title":"A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2017-10-01","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":38,"completionDate":"2020-11-01"},{"nctId":"NCT05914610","phase":"PHASE3","title":"Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2023-09-01","conditions":["Gastric Cancer"],"enrollment":100,"completionDate":"2028-07-30"},{"nctId":"NCT04267549","phase":"PHASE2","title":"Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-05-01","conditions":["Gastric Cancer Stage IV"],"enrollment":47,"completionDate":"2023-08-30"},{"nctId":"NCT00004860","phase":"PHASE2","title":"Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2000-10-09","conditions":["Colorectal Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT01845337","phase":"PHASE2","title":"Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-02-05","conditions":["Gastrointestinal Cancer","Cancer of Unknown Primary Site","Pancreatic Cancer","Bile Duct Neoplasms"],"enrollment":59,"completionDate":"2020-10-08"},{"nctId":"NCT05817201","phase":"PHASE2,PHASE3","title":"Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy","status":"UNKNOWN","sponsor":"Taizhou Hospital","startDate":"2022-07-01","conditions":["Esophageal Cancer","Radiation Therapy","Immunotherapy","Chemotherapy"],"enrollment":60,"completionDate":"2024-12-31"},{"nctId":"NCT05813015","phase":"PHASE3","title":"Study of Comparing of With and Without Sequential Therapy of S-1","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-01-28","conditions":["Locally Advanced Gastric Adenocarcinoma","Chemotherapy Effect"],"enrollment":70,"completionDate":"2026-12-31"},{"nctId":"NCT05774964","phase":"PHASE2","title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-15","conditions":["For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method"],"enrollment":100,"completionDate":"2025-03-15"},{"nctId":"NCT05769725","phase":"PHASE2","title":"A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-03-01","conditions":["Serplulimab,Gastric Cancer, Adjuvant Therapy"],"enrollment":70,"completionDate":"2026-03-31"},{"nctId":"NCT05325528","phase":"PHASE2,PHASE3","title":"Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-04-10","conditions":["Liver Metastases"],"enrollment":40,"completionDate":"2025-12-31"},{"nctId":"NCT02191566","phase":"PHASE2","title":"S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy","status":"TERMINATED","sponsor":"Kangbuk Samsung Hospital","startDate":"2015-05","conditions":["Stomach Cancer"],"enrollment":8,"completionDate":"2019-10"},{"nctId":"NCT05627414","phase":"PHASE2","title":"Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":["Gastric Cancer"],"enrollment":30,"completionDate":"2025-01-01"},{"nctId":"NCT05266300","phase":"","title":"Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2020-09-01","conditions":["Adverse Drug Event","Colon Cancer","Breast Cancer","Pancreas Cancer","Rectal Cancer","Gastric Cancer","Oesophageal Cancer","Bile Duct Cancer"],"enrollment":722,"completionDate":"2022-10-01"},{"nctId":"NCT05594381","phase":"PHASE2","title":"A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10","conditions":["Gastric Cancer"],"enrollment":90,"completionDate":"2025-10"},{"nctId":"NCT05529355","phase":"PHASE2","title":"Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Anhui Chest Hospital","startDate":"2022-09-18","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":45,"completionDate":"2023-09-18"},{"nctId":"NCT05468138","phase":"PHASE2","title":"PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-25","conditions":["MSI-H","PD-1 Immunotherapy","Gastric Cancer","Adjuvant Therapy"],"enrollment":141,"completionDate":"2025-12-31"},{"nctId":"NCT04856761","phase":"","title":"A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-11-01","conditions":["Biliary Tract Neoplasms","Recurrence","Cholangiocarcinoma","Gall Bladder Cancer"],"enrollment":160,"completionDate":"2024-12-30"},{"nctId":"NCT02749526","phase":"PHASE2","title":"Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial","status":"TERMINATED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-04","conditions":["Esophageal"],"enrollment":70,"completionDate":"2018-12"},{"nctId":"NCT05396326","phase":"PHASE1","title":"A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-06-01","conditions":["Gastric Cancer"],"enrollment":20,"completionDate":"2025-12-31"},{"nctId":"NCT05346874","phase":"PHASE2","title":"Neoadjuvant TACiE in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-06-01","conditions":["Gastric Cancer"],"enrollment":37,"completionDate":"2025-05-01"},{"nctId":"NCT03001726","phase":"","title":"To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-01","conditions":["Gastric Cancer"],"enrollment":228,"completionDate":"2023-12"}],"_emaApprovals":[{"date":"2011-03-14","status":"Authorised","company":"Nordic Group BV"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167181","NDDF":"007248","UNII":"1548R74NSZ","CHEBI":"CHEBI:32188","INN_ID":"4415","RXNORM":"4582","UMLSCUI":"C0016778","chemblId":"CHEMBL235993","ChEMBL_ID":"CHEMBL20883","KEGG_DRUG":"D01244","DRUGBANK_ID":"DB09256","PDB_CHEM_ID":" S7W","PUBCHEM_CID":"5386","SNOMEDCT_US":"395897006","IUPHAR_LIGAND_ID":"10513","MESH_DESCRIPTOR_UI":"D005641"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Nordic Group BV","relationship":"Original Developer"},{"period":"1999","companyName":"Taiho Pharmaceutical Co, Ltd","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"8.69 hours","clearance":"0.95 mL/min/kg","volumeOfDistribution":"0.62 L/kg"},"publicationCount":2339,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01BC03","allCodes":["L01BC03","L01BC53"]},"biosimilarFilings":[],"originalDeveloper":"Nordic Group BV","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Nordic Group BV","companyId":"nordic-group-bv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Florafur is a small molecule used in the treatment of various cancers, including locally advanced gastric adenocarcinoma, nasopharyngeal carcinoma, and breast cancer. It is often administered in combination with other treatments, such as docetaxel and S-1 (Tegafur-Gimeracil-Oteracil), as part of adjuvant therapy.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"1999-03-01T00:00:00.000Z","mah":"Taiho Pharmaceutical Co, Ltd","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2011-03-14T00:00:00.000Z","mah":"Nordic Group BV","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:30.846550+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}